Among all breast cancer patients diagnosed in Stockholm in 2014, triple-negative breast cancers constituted 8.2%, the HER2 type 13.8%, and the Luminal A and B types together represented 78.1% [27]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.